Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Melanoma 4Neoplasms 3Lymphoma, Non-Hodgkin 3Advanced Cancer 3Uveal Melanoma 2Recurrence 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Hodgkin Disease 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Various Advanced Cancer 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Sarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Site 1Microsatellite Unstable Colorectal Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrence × relatlimab × Clear all
NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

University of Pittsburgh

Phase 2 Completed
20 enrolled 13 charts
Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT02061761 2023-03-24

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Bristol-Myers Squibb

Phase 1/2 Completed
106 enrolled 27 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡